Media centre

Notes to editors

Background on Antisoma

Based in London, UK, Antisoma is a biotechnology company specialising in the development of novel drugs for the treatment of cancer.

Antisoma fills its development pipeline by acquiring promising new drug candidates from internationally recognised academic or cancer research institutions. The Company’s core activity is the preclinical and clinical development of these drug candidates.

Antisoma has a diverse portfolio of drugs in development. The company's cancer drugs target tumours by unique mechanisms and are intended for the treatment of a range of cancers. Antisoma also has a preclinical programme of DCAMs targeting wild type flt3 for auto-immune diseases.

Antisoma expects to bring products to market itself or through parterships with pharmaceutical companies.

Antisoma was founded in 1988 and its shares are traded on the London Stock Exchange. Antisoma is based at offices in London and Boston, MA.

Media contacts

For media enquiries please contact:

Alison Saville
enquiries@antisoma.com

Antisoma
Building 5, Chiswick Park
566, Chiswick High Road
London W4 5YF

Tel: +44 (0) 20 3249 2100
Fax: +44 (0) 20 3249 2101